Correlation analysis between CT findings and duration of initial symptoms in young and middle-aged patients with novel coronavirus pneumonia (preprint)

Objective: To retrospectively analyze the correlation between CT findings and duration of initial symptoms in young and middle-aged patients with novel coronavirus pneumonia.Materials and methods: From January 17, 2020 to February 4, 2020, of the 54 SARS-COV-2 infection cases, 48 cases (48/54,88.8%) were young and middle-aged patients under 60 years old. Finally, thirty-three patients under 60 years old with CT imaging were enrolled in this study, including 20 men and 13 women. Patients’ clinical data, including gender, age, infection exposure history, heating temperature, the initial symptoms and the duration, were recorded. The CT imaging features of pneumonia was scored. The number of lung lobe involvement and the length of the largest lesion were recorded. All above CT findings and clinical data were evaluated.Results: The median duration of initial symptoms was 3 days (range 0-7 days). The CT score and the length of the largest lesion showed statistically significant between the groups of initial symptom duration < 3 days and initial symptom duration ≥3 days (P<0.05). while age, gender, infection exposure history, fever temperature and the number of affected pulmonary lobes between the two groups had no significant difference (P>0.05). The duration of the initial symptom was positively correlated with both the CT score of pneumonia (r=0.502, P=0.003) and the length of the largest pneumonia lesion in the lung (r=0.506, P=0.003).Conclusion: The severity of pneumonia and the size of lesions were positively correlated with the duration of the initial symptom in young and middle-aged patients.

Thalidomide Combined with Low-dose Glucocorticoid in the Treatment of COVID-19 Pneumonia (preprint)

A novel coronavirus strain (severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first appeared in December 2019 and can cause acute respiratory distress syndrome and death. However, there are only limited therapy choices and no vaccine for SARS-CoV-2 is currently available. Here we report about a case of a SARS-CoV-2 caused pneumonia successfully treated with thalidomide. Thalidomide is an immunomodulatory and anti-inflammatory agent and was combined with a low-dose glucocorticoid. We suggest, that the effects of thalidomide might be related to regulating immunity, inhibiting the inflammatory cytokine surge, alleviating anxiety to reduce oxygen consumption, relieving vomit and lung exudation.